Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC).
Yip SM, Ruiz Morales JM, Donskov F, Fraccon A, Basso U, Rini BI, Lee JL, Bjarnason GA, Sim HW, Beuselinck B, Kanesvaran R, Brugarolas J, Koutsoukos K, Fu SYF, Yuasa T, Davis I, Alva A, Kollmannsberger C, Choueiri TK, Heng DYC. Yip SM, et al. Among authors: sim hw. Kidney Cancer. 2017 Jul 26;1(1):41-47. doi: 10.3233/KCA-160002. Kidney Cancer. 2017. PMID: 30334003 Free PMC article.
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Ruiz-Morales JM, Swierkowski M, Wells JC, Fraccon AP, Pasini F, Donskov F, Bjarnason GA, Lee JL, Sim HW, Sliwczynsk A, Ptak-Chmielewska A, Teter Z, Beuselinck B, Wood LA, Yuasa T, Pezaro C, Rini BI, Szczylik C, Choueiri TK, Heng DY. Ruiz-Morales JM, et al. Among authors: sim hw. Eur J Cancer. 2016 Sep;65:102-8. doi: 10.1016/j.ejca.2016.06.016. Epub 2016 Jul 31. Eur J Cancer. 2016. PMID: 27487293
First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.
Lalani AA, Li H, Heng DYC, Wood L, Kalirai A, Bjarnason GA, Sim HW, Kollmannsberger CK, Kapoor A, Hotte SJ, Vanhuyse M, Czaykowski P, Reaume MN, Soulieres D, Venner P, North S, Basappa NS. Lalani AA, et al. Among authors: sim hw. Can Urol Assoc J. 2017 Mar-Apr;11(3-4):112-117. doi: 10.5489/cuaj.4398. Can Urol Assoc J. 2017. PMID: 28515811 Free PMC article.
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, Yuasa T, Basappa NS, Kanesvaran R, Wood LA, Canil C, Kapoor A, Fu SYF, Choueiri TK, Heng DYC. Yip SM, et al. Among authors: sim hw. Cancer. 2018 Sep 15;124(18):3677-3683. doi: 10.1002/cncr.31595. Epub 2018 Oct 11. Cancer. 2018. PMID: 30307610 Free article.
Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies.
Kroeger N, Li H, De Velasco G, Donskov F, Sim HW, Stühler V, Wells JC, Stukalin I, Heide J, Bedke J, Agarwal N, Parekh H, Rini BI, Knox JJ, Pantuck A, Choueiri TK, Chin Heng DY. Kroeger N, et al. Among authors: sim hw. Clin Genitourin Cancer. 2019 Feb;17(1):65-71. doi: 10.1016/j.clgc.2018.09.006. Epub 2018 Sep 12. Clin Genitourin Cancer. 2019. PMID: 30341028
Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Donskov F, Xie W, Overby A, Wells JC, Fraccon AP, Sacco CS, Porta C, Stukalin I, Lee JL, Koutsoukos K, Yuasa T, Davis ID, Pezaro C, Kanesvaran R, Bjarnason GA, Sim HW, Rathi N, Kollmannsberger CK, Canil CM, Choueiri TK, Heng DYC. Donskov F, et al. Among authors: sim hw. Eur Urol Oncol. 2020 Aug;3(4):530-539. doi: 10.1016/j.euo.2020.01.001. Epub 2020 Feb 6. Eur Urol Oncol. 2020. PMID: 32037304 Free article.
Hepatocellular carcinoma in the era of immunotherapy.
Sim HW, Knox J. Sim HW, et al. Curr Probl Cancer. 2018 Jan-Feb;42(1):40-48. doi: 10.1016/j.currproblcancer.2017.10.007. Epub 2017 Nov 15. Curr Probl Cancer. 2018. PMID: 29150141 Review.
Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database.
Samawi HH, Sim HW, Chan KK, Alghamdi MA, Lee-Ying RM, Knox JJ, Gill P, Romagnino A, Batuyong E, Ko YJ, Davies JM, Lim HJ, Cheung WY, Tam VC; CHORD Consortium. Samawi HH, et al. Among authors: sim hw. Cancer Med. 2018 Jul;7(7):2816-2825. doi: 10.1002/cam4.1493. Epub 2018 May 15. Cancer Med. 2018. PMID: 29766659 Free PMC article.
Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma.
Jiang DM, Suzuki C, Espin-Garcia O, Lim CH, Ma LX, Sun P, Sim HW, Natori A, Chan BA, Moignard S, Chen EX, Liu G, Swallow CJ, Darling GE, Wong R, Jang RW, Elimova E. Jiang DM, et al. Among authors: sim hw. Cancer Med. 2020 May;9(9):3023-3032. doi: 10.1002/cam4.2948. Epub 2020 Mar 4. Cancer Med. 2020. PMID: 32130793 Free PMC article.
Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS, Tam VC, Meyers DE, Sim HW, Knox JJ, Zaborska V, Davies J, Ko YJ, Batuyong E, Samawi H, Cheung WY, Lee-Ying R. Fung AS, et al. Among authors: sim hw. Cancer Med. 2020 Jul;9(13):4640-4647. doi: 10.1002/cam4.3116. Epub 2020 May 7. Cancer Med. 2020. PMID: 32378799 Free PMC article.
101 results